Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
Who We Are
Our mission is to create medicines that can achieve extraordinary outcomes for people affected by severe diseases.
Our team
The potential impact of our approach has attracted a passionate team of talented individuals and advisors who are recognized leaders across clinical development, data science, biology, peptide chemistry, and business execution. We are also proud to have the backing of a robust group of blue-chip life sciences investors.
- Leadership
- Board
- Investors
Investors
